

Ann M Leen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4535672/publications.pdf>

Version: 2024-02-01

81
papers

4,951
citations

186209

28
h-index

138417

58
g-index

81
all docs

81
docs citations

81
times ranked

4677
citing authors

#	ARTICLE	IF	CITATIONS
1	Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. <i>Nature Medicine</i> , 2006, 12, 1160-1166.	15.2	536
2	Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. <i>Blood</i> , 2013, 121, 5113-5123.	0.6	507
3	Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 3547-3557.	0.8	367
4	Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT. <i>Science Translational Medicine</i> , 2014, 6, 242ra83.	5.8	357
5	Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. <i>Blood</i> , 2009, 114, 4283-4292.	0.6	311
6	Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. <i>Blood</i> , 2007, 110, 2838-2845.	0.6	266
7	Improving T Cell Therapy for Cancer. <i>Annual Review of Immunology</i> , 2007, 25, 243-265.	9.5	233
8	Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. <i>Molecular Therapy</i> , 2017, 25, 249-258.	3.7	217
9	Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor. <i>Molecular Therapy</i> , 2014, 22, 1211-1220.	3.7	145
10	Fine-tuning the CAR spacer improves T-cell potency. <i>Oncolmmunology</i> , 2016, 5, e1253656.	2.1	137
11	Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. <i>Blood</i> , 2004, 104, 2432-2440.	0.6	129
12	Adenovirus as an emerging pathogen in immunocompromised patients. <i>British Journal of Haematology</i> , 2005, 128, 135-144.	1.2	129
13	Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy. <i>Journal of Virology</i> , 2008, 82, 546-554.	1.5	129
14	Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1498-1505.e1.	1.5	117
15	Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells. <i>Molecular Therapy</i> , 2014, 22, 623-633.	3.7	113
16	Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. <i>Cancer Discovery</i> , 2018, 8, 972-987.	7.7	93
17	CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. , 2018, 6, 34.		85
18	Generation of Tumor Antigen-Specific T Cell Lines from Pediatric Patients with Acute Lymphoblastic Leukemia—Implications for Immunotherapy. <i>Clinical Cancer Research</i> , 2013, 19, 5079-5091.	3.2	81

#	ARTICLE	IF	CITATIONS
19	Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma. <i>Molecular Therapy</i> , 2011, 19, 2258-2268.	3.7	80
20	Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. <i>Clinical Cancer Research</i> , 2017, 23, 3499-3509.	3.2	76
21	Optimizing the production of suspension cells using the G-Rex "series. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014, 1, 14015.	1.8	71
22	Antiviral T-cell therapy. <i>Immunological Reviews</i> , 2014, 258, 12-29.	2.8	58
23	General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1284-1290.	2.0	51
24	Adenoviral Infections in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 243-251.	2.0	50
25	Is cancer gene therapy an empty suit?. <i>Lancet Oncology</i> , The, 2013, 14, e447-e456.	5.1	48
26	Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. <i>Blood</i> , 2021, 137, 2585-2597.	0.6	38
27	Cytotoxic T lymphocytes as immune therapy in haematological practice. <i>British Journal of Haematology</i> , 2008, 143, 169-179.	1.2	35
28	Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 337-351.	1.4	31
29	T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. <i>Journal of Clinical Oncology</i> , 2021, 39, 1415-1425.	0.8	30
30	Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. , 2021, 9, e003237.		29
31	Systemic Inflammatory Response Syndrome After Administration of Unmodified T Lymphocytes. <i>Molecular Therapy</i> , 2014, 22, 1134-1138.	3.7	28
32	Graft Versus Leukemia Response Without Graft-versus-host Disease Elicited By Adoptively Transferred Multivirus-specific T-cells. <i>Molecular Therapy</i> , 2015, 23, 179-183.	3.7	28
33	Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoietic stem cell transplant patients. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 292-300.	1.3	27
34	Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections. <i>Haematologica</i> , 2020, 105, 235-243.	1.7	26
35	The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	25
36	A New Method for Reactivating and Expanding T Cells Specific for <i>Rhizopus oryzae</i> . <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 9, 305-312.	1.8	24

#	ARTICLE	IF	CITATIONS
37	Contact-activated Monocytes: Efficient Antigen Presenting Cells for the Stimulation of Antigen-specific T cells. <i>Journal of Immunotherapy</i> , 2007, 30, 96-107.	1.2	23
38	Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy. <i>Journal of Infectious Diseases</i> , 2017, 216, 678-687.	1.9	23
39	Characterizing the Cellular Immune Response to Parainfluenza Virus 3. <i>Journal of Infectious Diseases</i> , 2017, 216, 153-161.	1.9	19
40	Engineered T cells for cancer treatment. <i>Cytotherapy</i> , 2014, 16, 713-733.	0.3	18
41	Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. , 2019, 7, 330.		18
42	Epstein-Barr Virus (EBV)-derived BART1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. <i>Cytotherapy</i> , 2019, 21, 212-223.	0.3	16
43	Preventing stem cell transplantation-associated viral infections using T-cell therapy. <i>Immunotherapy</i> , 2015, 7, 793-810.	1.0	15
44	Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus. <i>Journal of Virology</i> , 2018, 92, .	1.5	13
45	Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL. <i>Blood</i> , 2022, 139, 2706-2711.	0.6	13
46	Accelerating immune reconstitution after hematopoietic stem cell transplantation. <i>Clinical and Translational Immunology</i> , 2014, 3, e11.	1.7	11
47	Identification of protective T-cell antigens for smallpox vaccines. <i>Cytotherapy</i> , 2020, 22, 642-652.	0.3	10
48	A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report.. <i>Journal of Clinical Oncology</i> , 2020, 38, 716-716.	0.8	9
49	A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4622-4622.	0.8	9
50	Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 911-919.	2.0	8
51	Immune-Based Therapies Targeting MAGE-A4 for Relapsed/Refractory Hodgkin's Lymphoma After Stem Cell Transplant.. <i>Blood</i> , 2009, 114, 4089-4089.	0.6	7
52	Adoptive T cell therapy for the treatment of viral infections. <i>Annals of Translational Medicine</i> , 2015, 3, 278.	0.7	7
53	Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211071.	1.4	6
54	Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 387-397.	2.5	4

#	ARTICLE	IF	CITATIONS
55	Generation of Multi-Antigen Specific T Cells for Adoptive Immunotherapy of Myeloid Leukemia and Identification of MHC Class I and II-Restricted Peptides for WT1, Proteinase 3 and Human Neutrophil Elastase. Blood, 2011, 118, 2985-2985.	0.6	4
56	Adoptive immunotherapy for herpesviruses. , 2007, , 1318-1331.		2
57	Overcoming the breast tumor microenvironment by targeting MDSCs through CAR-T cell therapy.. Journal of Clinical Oncology, 2021, 39, 1032-1032.	0.8	2
58	Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2016, 128, 501-501.	0.6	2
59	Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19. Blood, 2020, 136, 5-5.	0.6	2
60	Allogeneic Virus-Specific T Cells with HLA Alloreactivity Do Not Produce Graft-Versus-Host Disease In Human Subjects. Blood, 2010, 116, 1252-1252.	0.6	1
61	Combining Oncolytic Vaccinia Virotherapy with Adoptive T Cell Therapy,. Blood, 2011, 118, 4042-4042.	0.6	1
62	Safety and Preliminary Efficacy of "Ready to Administer" Cytomegalovirus (CMV)-Specific T Cells for the Treatment of Patients with Refractory CMV Infection. Blood, 2016, 128, 388-388.	0.6	1
63	Retrovirus-Transduced T Cell Blasts Have Not Only Antigen-Presenting Capabilities but Also Suppressor Regulatory T Cell-Inducing Capability.. Blood, 2004, 104, 3855-3855.	0.6	0
64	The Clinical Use of Donor-Derived Virus-Specific Cytotoxic T Lymphocytes Reactive Against Cytomegalovirus (CMV), Adenovirus and Epstein Barr Virus (EBV).. Blood, 2005, 106, 81-81.	0.6	0
65	Complete Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T Lymphocytes Targeting EBV Latent Membrane Proteins. Blood, 2008, 112, 230-230.	0.6	0
66	Multivirus-Specific T Cell Immunotherapy to Prevent or Treat Infections of Stem Cell Transplant Recipients.. Blood, 2008, 112, 2207-2207.	0.6	0
67	The "Side-Population" of Human Lymphoma Cells Have Increased Chemo-Resistance, Stem-Cell Like Properties and Are Potential Targets for Immunotherapy. Blood, 2008, 112, 2620-2620.	0.6	0
68	Rapid Generation of Antigen-Specific T Cells for Pre-Clinical and Clinical Applications Using a Novel Mini Cell Bioreactor. Blood, 2008, 112, 208-208.	0.6	0
69	Exploiting Cytokine Secretion to Rapidly Produce Multivirus-Specific T Cells for Adoptive Immunotherapy. Blood, 2008, 112, 4594-4594.	0.6	0
70	Cytotoxic T Lymphocytes (CTL) Specific for Adenovirus and CMV Can Be Generated from Umbilical Cord Blood for Adoptive Immunotherapy. Blood, 2008, 112, 3505-3505.	0.6	0
71	Safely Improving the in Vivo Survival of Tumor Specific Cytotoxic T Lymphocytes by Co-Transfer of IL7 Receptor Alpha Chain and icaspase9. Blood, 2008, 112, 3534-3534.	0.6	0
72	Cytotoxic T Lymphocytes (CTL) Specific for CMV, Adenovirus, and EBV Can Be Generated From Naive T Cells for Adoptive Immunotherapy.. Blood, 2009, 114, 504-504.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Detection and Ex Vivo Expansion of Anti-Viral T Cells Isolated From Recipients of Unrelated Umbilical Cord Blood Transplant.. Blood, 2009, 114, 2245-2245.	0.6	0
74	Adverse Events Following Infusion of T Cells for Adoptive Immunotherapy: A 10 Year Experience.. Blood, 2009, 114, 3212-3212.	0.6	0
75	Despite Absence of Measurable Immune Responses against Adenovirus in the First 100 Days After Unrelated Umbilical Cord Blood Transplant in Vitro amplification Strategies Can Unveil Hexon and Penton-Specific Immunity.. Blood, 2009, 114, 4640-4640.	0.6	0
76	Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies,. Blood, 2011, 118, 4043-4043.	0.6	0
77	Human Papillomavirus Type 16 (HPV16) E6/E7-Specific Cytotoxic T Lymphocytes (CTLs) for Immunotherapy of HPV-Associated Malignancies. Blood, 2011, 118, 1913-1913.	0.6	0
78	Human papillomavirus type 16 (HPV16) E6/E7-specific cytotoxic T lymphocytes (CTL) for immunotherapy of HPV-associated cancer (Ca).. Journal of Clinical Oncology, 2012, 30, 2558-2558.	0.8	0
79	Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2015, 126, 622-622.	0.6	0
80	Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years. Blood, 2015, 126, 1926-1926.	0.6	0
81	Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL. Blood, 2021, 138, 471-471.	0.6	0